CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.
← catalyst calendarNCT07742839 · readout in 325 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
168estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-30 | estimated | When the study began enrolling |
| Primary completion | 2027-07-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Appendage
Intervention
- Device: Edwards ECLIPTIS Left Atrial Appendage Exclusion System
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants who have device technical success
measured Intra-operative
Participant's rate of major clinically significant adverse events
measured 30 days
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed